2025 Seattle Cellular Therapy Summit

Seattle, WA US
August 15, 2025 to August 16, 2025

Overview

This CME-accredited activity, 2025 Seattle Cellular Therapy Summit, features leading experts who will provide a comprehensive overview of current and emerging strategies for the management of lymphoma, myeloma, acute leukemias, and solid tumors with a focus in the use of cellular therapies. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies and to describe potential future applications of cellular therapy in solid tumors. The activity will use a mix of didactic lectures and case-based discussions to highlight areas of debate between cellular therapy and non-cellular therapy in the treatment of these diseases. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care. The faculty will discuss barriers to using cellular therapy and discuss evidence-based strategies to navigate these barriers to incorporate the new standards of care in managing patients with cancer.

The symposium will augment healthcare providers' foundation of knowledge and clinical competence in several areas:

  • Providing a review of existing clinical evidence supporting approved Chimeric Antigen Receptor T-cell (CAR T) therapies in the care of patients with hematologic malignancies
  • Describing the role of non-cellular therapies in hematologic malignancies
  • Identify challenges to the delivery of cellular therapies and provide a discussion on how such barriers may be addressed
  • Discussing novel investigational approaches of cellular therapy in acute myeloid leukemias and solid tumors

Target Audience

  • Hematologists/Medical Oncologists 
  • Oncology Fellows
  • Oncology Nurses
  • NPs/PAs
  • Oncology Pharmacists

Organizing Committee

Conference Director: 

  • Binay Shah, MD, MHA - Binaytara

Conference Co-Chairs:

  • Mazyar Shadman, MD, MPH - Fred Hutchinson Cancer Center & University of Washington
  • Krish Patel, MD - Sarah Cannon Research Institute

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review indications and outcomes of approved cellular therapies in hematologic malignancies
  • Identify emerging cellular therapies in hematologic malignancies and solid tumors
  • Identify and manage complications after cellular therapy
  • State the financial, physical, and other barriers, review strategies to navigate these factors to optimize the management of patients with cellular therapies

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 13.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 13.00 ACPE Pharmacy

    The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-010-L01-P

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

    ACPE Pharmacy
  • 13.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 13.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 13.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 13.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 13.00 Contact Hours.
Course opens: 
02/01/2025
Course expires: 
11/16/2025
Event starts: 
08/15/2025 - 7:00am PDT
Event ends: 
08/16/2025 - 4:30pm PDT
Cost:
$300.00
Add to calendar: 
Rating: 
0

Program

Day 1 - August 15, 2025

All times are listed in Pacific Time (PT)

09:00 AM – 10:00 AM  Registration, Breakfast, & Exhibits

10:00 AM – 10:15 AM  Welcome and Opening Remarks

10:15 AM – 11:15 AM  Session 1: Solid Tumors I

Session Chair:

10:15 AM – 10:30 AM  Immuno-oncology for Solid Tumors: Are We Getting Closer?  -

10:30 AM – 10:45 AM  Lung Cancer: Tarlatamab -

10:45 AM – 11:00 AM  Malignant Melanoma: Lifileucel and Beyond -

11:00 AM – 11:15 AM  Sarcoma: Afamitresgene Autoleucel -

11:15 AM – 12:15 PM  Session 2: Solid Tumors II

Session Chair:

11:15 AM – 11:30 AM  GU Malignancies: What is on the Horizon for Cellular Therapy? -

11:30 AM – 11:45 AM  CLL - GI Malignancies: What is on the Horizon for Cellular Therapy? -

11:45 AM – 12:15 PM  Panel Discussion 

12:15 PM – 01:15 PM  Lunch & Exhibits

01:15 PM – 02:30 PM  Session 3: Autoimmune Diseases

Session Chair:

01:15 PM – 01:30 PM  Immunotherapy for Rheumatologic Disorders - 

01:30 PM – 01:45 PM  Immunotherapy for Neuroimmune Disorders - 

01:45 PM – 02:00 PM  Bispecific Antibodies for Autoimmune Disorders - 

02:00 PM – 02:30 PM  Panel Discussion

02:30 PM – 02:45 PM  Break & Exhibits

02:45 PM – 03:45 PM Session 4: Acute Leukemia

Session Chair:

02:45 PM – 03:00 PM  Myeloid Malignancies: What is on the Horizon for Immunotherapy? -

03:00 PM – 03:15 PM  Immunotherapy for Myeloid Malignancies: Challenges and Promises - 

03:15 PM – 03:30 PM  ALL: Focus on Immunotherapeutic Approaches, Approved and Investigational Options - 

03:30 PM – 03:45 PM  Panel Discussion

03:45 PM – 04:45 PM Session 5: Chronic Lymphocytic Leukemia

Session Chair: 

03:45 PM – 04:00 PM  How I Treat CLL in 2025 -

04:00 PM – 04:15 PM  CLL: Focus on immunotherapeutic approaches, approved and investigational options - 

04:15 PM – 04:45 PM  Panel Discussion 

04:45 PM  Adjourn

04:45 PM  – 05:30 PM  Networking Reception

 

Day 2 - August 16, 2025

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits

08:00 AM – 09:30 AM  Session 6: Barriers to Cellular Immunotherapy

Session Chair:

08:00 AM – 08:15 AM  Improving Accessibility and Sustainability of Cellular Therapy - Navneet Majhail, MD

08:15 AM – 08:30 AM  From Community to CAR-T Centers: What We Know About Attrition

08:30 AM – 08:45 AM  Initiative to Improve Access to Immunotherapy for Solid Tumors

08:45 AM – 09:00 AM  Strategies to Relax the Current Requirements for CAR-T Therapy  

09:00 AM – 09:30 AM  Panel Discussion 

09:30 AM – 10:00 AM  Session 7: Global Oncology

Session Chair:

10:00 AM – 10:15 AM  Break & Exhibits

10:15 AM – 11:15 AM  Session 8: Aggressive B-Cell Lymphoma 

Session Chair:

10:15 AM – 10:30 AM  How I treat DLBCL in 2025 - 

10:30 AM – 10:45 AM  DLBCL: Focus on Immunotherapeutic Approaches, Approved and Investigational Options -

10:45 AM – 11:15 AM  Panel Discussion

11:15 AM – 12:00 PM  Session 9: Indolent B-Cell Lymphoma 

11:15 AM – 11:30 AM  How I Treat FL in 2025 -

11:30 AM – 11:45 AM  FL: Focus on Immunotherapeutic Approaches, Approved and Investigational Options -

11:45 AM – 12:00 PM  Panel Discussion - Ryan Jacobs, MD 

12:00 PM – 01:00 PM  Lunch & Exhibits

01:00 PM – 01:45 PM  Session 10: Mantle Cell Lymphoma

Session Chair:

01:00 PM – 01:15 PM  How I Treat MCL in 2025 -

01:15 PM – 01:30 PM  MCL: Focus on Immunotherapeutic Approaches, Approved and Investigational Options -

01:30 PM – 01:45 PM  Panel Discussion 

01:45 PM – 02:15 PM  Keynote Lecture: Challenges and Promises of Cellular Immunotherapies in Hematologic Malignancies -

02:15 PM – 04:00 PM  Session 11: Multiple Myeloma

Session Chair:

02:15 PM – 02:30 PM  How I Treat Previously Untreated MM in 2025 -

02:30 PM – 02:45 PM  MM: Focus on CAR-T, Approved Agents -

02:45 PM – 03:00 PM  MM: Focus on Bispecific Antibodies, Approved Agents - 

03:00 PM – 03:15 PM  MM: Update on Investigational Immunotherapeutic Treatments for MM -

03:15 PM – 03:30 PM  Smoldering Myeloma: Controversies in 2025 - 

03:30 PM – 04:00 PM  Panel Discussion

04:00 PM – 04:15 PM  Break & Exhibits

04:15 PM – 05:15 PM  Session 12: Complications and Supportive Care

Session Chair:

04:15 PM – 04:30 PM  CRS/ICANS Management in 2025: From Standard Practice to Research - 

04:30 PM – 04:45 PM  Prolonged Cytopenia after CAR-T - 

04:45 PM – 05:00 PM  Diagnosis and Management of IEC-HS - 

05:00 PM – 05:15 PM  Second Malignancies after CAR-T Therapy -

05:15 PM  Adjourn

Venue

Bell Harbor International Conference Center
2211 Alaskan Way
Seattle, WA 98121
United States
Bell Harbor International Conference Center

Hotel Reservation Details Coming Soon!

 

Faculty

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Swetha Thiruvengadam

has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Independent contractor) with AbbVie;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Independent contractor) with Ipsen;.
has a financial relationship (Professional Services) with Genmab/AbbVie;.
has a financial relationship (Independent contractor) with Kite Pharmaceuticals;.
has a financial relationship (Professional Services) with Genentech;.
Conference Chair(s)

Krish Patel, MD

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Sana;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Fate Therapeutics;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with Janssen/Pharmacyclics;.
has a financial relationship (Professional Services) with Xencor;.

Mazyar Shadman, MD,MPH

has a financial relationship (Professional Services) with Mustang Bio ;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Employment) with BMS;.
has a financial relationship (Professional Services) with Kite Pharma ;.
has a financial relationship (Professional Services) with Nurix;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with MorphoSys/Incyte;.
has a financial relationship (Professional Services) with Janssen ;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Genmab;.
has a financial relationship (Stock Options) with Koi Biotherapeutics;.
has a financial relationship (Professional Services) with Fate therapeutics;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Vincerx ;.
has a financial relationship (Professional Services) with Eli Lily ;.
Speaker/Topic Presenter(s)

Navneet Majhail, MD, MS, FASTCT

has a financial relationship (Independent contractor) with Anthem Inc;.

Nirav Shah, MD

has a financial relationship (Independent contractor) with Tundra Therapeutics;.
has a financial relationship (Independent contractor) with Incyte;.
has a financial relationship (Independent contractor) with TG Therapeutics;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Galapagos;.
has a financial relationship (Independent contractor) with Gilead-Kite;.
has a financial relationship (Independent contractor) with Seattle Genetics;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with Miltenyi Biotec;.
has a financial relationship (Independent contractor) with BMS-Juno;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Independent contractor) with Lilly Oncology;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Epizyme;.
has a financial relationship (Independent contractor) with Cargo;.
Moderator(s)

Paolo Strati, MD

has a financial relationship (Professional Services) with Astrazeneca;.
has a financial relationship (Professional Services) with Genmab Abbvie;.
has a financial relationship (Professional Services) with Roche Genentech;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with Kite-Gilead;.
has a financial relationship (Professional Services) with Ipsen;.

Accreditation

Available Credit

  • 13.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 13.00 ACPE Pharmacy

    The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-010-L01-P

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

    ACPE Pharmacy
  • 13.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 13.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 13.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 13.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 13.00 Contact Hours.

Exhibitors

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

Register/Take course

Price

Cost:
$300.00
Please login or register to take this course.

REGISTRATION FEES 

Physicians (non-industry) - $300

Non-physician HCP (non-industry) - $200

Industry representatives - $1250

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme .

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

Attend Only Registration Terms & Conditions:

Employees of companies that have not purchased an exhibit space or are not a sponsor of the conference should refrain from interacting with healthcare provider attendees outside of the main meeting room. This applies to ALL interactions except for asking content-relevant questions to faculty inside the meeting room where the CME-accredited activity occurs. Please do not engage in product promotion activity with any attendees or faculty of the conference. 

If your company has not purchased an exhibit space or sponsorship, and you engage in any promotional activity, including but not limited to introducing yourself to healthcare providers as an employee of the company, handing out business cards and product brochures/flyers, setting up visits/appointments, inviting them to promotional talks, etc., we will invoice YOU for the full cost of a premium exhibit table.

If your company has not purchased an exhibit space or sponsorship, please limit your interaction with healthcare providers attending this conference to "hello" only if you know the provider. Failure to comply with this requirement may result in being banned from all future conferences.

Employees of companies who are not exhibiting or sponsoring the conference may not enter the exhibit area. The exhibit area is ONLY for exhibitors and sponsors to engage in sales activity. Many of our conferences have meals in the exhibit hall; if the meal is in the exhibit hall, you will need to make alternative arrangements for your meals as you will not be provided meals by the meeting.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post-tests as well as course evaluations.